These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38567606)

  • 1. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
    Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
    Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
    Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
    Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
    Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biallelic, Selectable, Knock-in Targeting of CCR5
    Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
    Front Immunol; 2022; 13():821190. PubMed ID: 35386712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
    Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
    Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
    Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population.
    Apostolakis S; Baritaki S; Krambovitis E; Spandidos DA
    J Clin Virol; 2005 Dec; 34(4):310-4. PubMed ID: 16286055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
    Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
    Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users.
    Alvarez V; López-Larrea C; Coto E
    Hum Genet; 1998 Apr; 102(4):483-6. PubMed ID: 9600249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
    Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
    Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers.
    Solloch UV; Lang K; Lange V; Böhme I; Schmidt AH; Sauter J
    Hum Immunol; 2017 Nov; 78(11-12):710-717. PubMed ID: 28987960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape.
    Hütter G; Bodor J; Ledger S; Boyd M; Millington M; Tsie M; Symonds G
    Viruses; 2015 Jul; 7(8):4186-203. PubMed ID: 26225991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of the CCR5 delta 32 mutant allele in HIV-1-positive patients, female sex workers, and a normal population in Taiwan.
    Li C; Yan YP; Shieh B; Lee CM; Lin RY; Chen YM
    J Formos Med Assoc; 1997 Dec; 96(12):979-84. PubMed ID: 9444918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR5-Δ32 gene variant frequency in the Turkish Cypriot population.
    Fahrioglu U; Ergoren MC; Mocan G
    Braz J Microbiol; 2020 Dec; 51(4):1711-1717. PubMed ID: 32734471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CCR5-Δ32 mutation among individuals with high risk behaviors, neonates born to HIV-1 infected mothers, HIV-1 infected individuals, and healthy people in an Iranian population.
    Donyavi T; Bokharaei-Salim F; Nahand JS; Garshasbi S; Esghaei M; Sadeghi M; Jamshidi S; Khanaliha K
    J Med Virol; 2020 Aug; 92(8):1158-1164. PubMed ID: 31854469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CC chemokine receptor 5 Δ32 polymorphism: association analysis and allele distribution among cutaneous leishmaniasis patients from Pakistan.
    Sophie M; Hameed A; Muneer A; Samdani AJ; Saleem S; Azhar A
    J Cutan Pathol; 2016 Jul; 43(7):564-70. PubMed ID: 26970327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the CCR5-Delta32 HIV resistance allele and new mutations of the CCR5 gene in different Tunisian populations.
    Jlizi A; Edouard J; Fadhlaoui-Zid K; Frigi S; Debré P; Slim A; Theodorou I; El Gaaied AB; Carpentier W
    Hum Immunol; 2007 Dec; 68(12):993-1000. PubMed ID: 18191728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous Hematopoietic Stem Cells transplantation and genetic modification of CCR5 m303/m303 mutant patient for HIV/AIDS.
    Esmaeilzadeh A; Farshbaf A; Erfanmanesh M
    Med Hypotheses; 2015 Mar; 84(3):216-8. PubMed ID: 25613565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Efficiency for Biallelic Mutations of the
    Lin D; Scheller SH; Robinson MM; Izadpanah R; Alt EU; Braun SE
    CRISPR J; 2021 Feb; 4(1):92-103. PubMed ID: 33616448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.